NASDAQ:SBPH - Spring Bank Pharmaceuticals Stock Price, Price Target & More

$14.26 +0.10 (+0.71 %)
(As of 04/20/2018 05:24 AM ET)
Previous Close$14.16
Today's Range$14.21 - $14.39
52-Week Range$8.47 - $18.93
Volume7,579 shs
Average Volume26,626 shs
Market Capitalization$183.24 million
P/E Ratio-7.63
Dividend YieldN/A
Beta-0.35

About Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Spring Bank Pharmaceuticals logoSpring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).

Receive SBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SBPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBPH
CUSIPN/A
Phone508-473-5993

Debt

Debt-to-Equity RatioN/A
Current Ratio11.54%
Quick Ratio11.54%

Price-To-Earnings

Trailing P/E Ratio-7.63
Forward P/E Ratio-5.94
P/E GrowthN/A

Sales & Book Value

Annual Sales$350,000.00
Price / Sales528.03
Cash FlowN/A
Price / CashN/A
Book Value$2.68 per share
Price / Book5.32

Profitability

EPS (Most Recent Fiscal Year)($1.87)
Net Income$-27,670,000.00
Net MarginsN/A
Return on Equity-69.68%
Return on Assets-44.86%

Miscellaneous

Employees21
Outstanding Shares12,960,000

How to Become a New Pot Stock Millionaire

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions

What is Spring Bank Pharmaceuticals' stock symbol?

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

How were Spring Bank Pharmaceuticals' earnings last quarter?

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) issued its quarterly earnings results on Tuesday, February, 20th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.18. View Spring Bank Pharmaceuticals' Earnings History.

What price target have analysts set for SBPH?

5 Wall Street analysts have issued 1-year price objectives for Spring Bank Pharmaceuticals' stock. Their predictions range from $20.00 to $32.00. On average, they expect Spring Bank Pharmaceuticals' share price to reach $28.00 in the next year. View Analyst Ratings for Spring Bank Pharmaceuticals.

Who are some of Spring Bank Pharmaceuticals' key competitors?

When did Spring Bank Pharmaceuticals IPO?

(SBPH) raised $14 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.

Has Spring Bank Pharmaceuticals been receiving favorable news coverage?

Press coverage about SBPH stock has trended somewhat negative recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of -0.06 on Accern's scale. They also assigned media stories about the company an impact score of 47.37 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Spring Bank Pharmaceuticals?

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spring Bank Pharmaceuticals' stock price today?

One share of SBPH stock can currently be purchased for approximately $14.26.

How big of a company is Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals has a market capitalization of $183.24 million and generates $350,000.00 in revenue each year. The company earns $-27,670,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 21 workers across the globe.

How can I contact Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals' mailing address is 86 South Street, Hopkinton MA, 01748. The company can be reached via phone at 508-473-5993.


MarketBeat Community Rating for Spring Bank Pharmaceuticals (SBPH)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe SBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Spring Bank Pharmaceuticals in the last 12 months. Their average twelve-month price target is $28.00, suggesting that the stock has a possible upside of 96.35%. The high price target for SBPH is $32.00 and the low price target for SBPH is $20.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.802.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.00$28.00$27.25$26.3333
Price Target Upside: 96.35% upside138.30% upside60.11% upside73.02% upside

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Consensus Price Target History

Price Target History for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018Cantor FitzgeraldReiterated RatingOverweight -> Overweight$29.00 -> $32.00LowView Rating Details
11/6/2017Chardan CapitalReiterated RatingBuyN/AView Rating Details
11/6/2017B. RileyInitiated CoverageBuy -> Buy$30.00N/AView Rating Details
8/7/2017Dawson JamesReiterated RatingBuyLowView Rating Details
5/19/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Market Perform$20.00MediumView Rating Details
8/19/2016William BlairInitiated CoverageOutperform$26.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Earnings History and Estimates Chart

Earnings by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Earnings Estimates

2018 EPS Consensus Estimate: ($1.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.52)($0.46)($0.49)
Q2 20182($0.53)($0.45)($0.49)
Q3 20182($0.53)($0.44)($0.49)
Q4 20182($0.53)($0.43)($0.48)

Spring Bank Pharmaceuticals (NASDAQ SBPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018Q4 2017($0.65)($0.47)ViewN/AView Earnings Details
10/31/2017Q3 2017($0.46)($0.39)ViewN/AView Earnings Details
7/31/2017Q2 2017($0.48)($0.54)ViewN/AView Earnings Details
4/28/20173/31/2017($0.47)($0.47)ViewN/AView Earnings Details
2/15/2017Q4 2016($0.61)($0.51)ViewN/AView Earnings Details
10/31/2016Q3 2016($0.59)($0.53)ViewN/AView Earnings Details
8/1/2016Q2 2016($0.62)$0.07 millionViewN/AView Earnings Details
6/15/2016Q1 2016($1.11)$0.28 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Spring Bank Pharmaceuticals (NASDAQ SBPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.60%
Institutional Ownership Percentage: 28.65%
Insider Trading History for Spring Bank Pharmaceuticals (NASDAQ:SBPH)
Institutional Ownership by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Spring Bank Pharmaceuticals (NASDAQ SBPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/28/2018Martin J DriscollInsiderBuy1,000$12.83$12,830.00View SEC Filing  
9/14/2017Martin J DriscollInsiderBuy1,000$14.84$14,840.0055,400View SEC Filing  
8/4/2017David ArkowitzDirectorBuy2,500$12.24$30,600.0017,086View SEC Filing  
8/3/2017Martin J DriscollInsiderBuy2,000$12.36$24,720.0053,400View SEC Filing  
6/27/2017Kurt M EichlerDirectorBuy76,923$13.00$999,999.00582,533View SEC Filing  
3/7/2017Martin J DriscollInsiderBuy2,000$9.44$18,880.0052,400View SEC Filing  
2/23/2017Kurt M EichlerDirectorBuy1,200$8.76$10,512.00505,610View SEC Filing  
12/15/2016Martin J DriscollInsiderBuy2,000$8.50$17,000.0050,400View SEC Filing  
11/30/2016Martin J DriscollInsiderBuy2,000$7.98$15,960.0048,400View SEC Filing  
11/9/2016Kurt M EichlerDirectorBuy7,000$8.69$60,830.00437,990View SEC Filing  
11/9/2016Martin J DriscollInsiderBuy2,000$8.84$17,680.0024,500View SEC Filing  
9/19/2016Kurt M EichlerDirectorBuy1,996$12.50$24,950.00429,644View SEC Filing  
9/14/2016Kurt M EichlerDirectorBuy514$12.50$6,425.00428,994View SEC Filing  
9/13/2016Kurt M EichlerDirectorBuy490$12.50$6,125.00428,480View SEC Filing  
9/9/2016Nezam H AfdhalInsiderBuy2,400$12.50$30,000.0040,150View SEC Filing  
9/2/2016Martin J DriscollInsiderBuy1,000$11.75$11,750.0022,500View SEC Filing  
8/30/2016Martin J DriscollInsiderBuy1,000$12.41$12,410.0021,500View SEC Filing  
8/24/2016Nezam H AfdhalInsiderBuy2,000$11.92$23,840.0037,300View SEC Filing  
8/23/2016Jonathan FreveCFOBuy1,000$10.74$10,740.002,000View SEC Filing  
8/23/2016Kurt M EichlerDirectorBuy3,000$10.73$32,190.00427,990View SEC Filing  
8/22/2016Martin J DriscollInsiderBuy2,000$11.43$22,860.0019,500View SEC Filing  
8/16/2016Nezam H AfdhalInsiderBuy1,900$11.43$21,717.0035,650View SEC Filing  
8/12/2016Nezam H AfdhalInsiderBuy2,600$11.33$29,458.0033,850View SEC Filing  
8/9/2016Martin J DriscollInsiderBuy2,000$11.03$22,060.0015,500View SEC Filing  
8/4/2016Jonathan FreveCFOBuy1,000$9.75$9,750.001,000View SEC Filing  
8/4/2016Martin J DriscollInsiderBuy2,000$9.96$19,920.0013,500View SEC Filing  
5/11/2016Kurt M EichlerDirectorBuy41,666$12.00$499,992.00423,990View SEC Filing  
5/11/2016Martin J DriscollCEOBuy12,500$12.00$150,000.0012,500View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spring Bank Pharmaceuticals (NASDAQ SBPH) News Headlines

Source:
DateHeadline
Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™
finance.yahoo.com - April 18 at 10:03 AM
Spring Bank Pharmaceuticals (SBPH) PT Lowered to $30.00 at Chardan CapitalSpring Bank Pharmaceuticals (SBPH) PT Lowered to $30.00 at Chardan Capital
www.americanbankingnews.com - April 14 at 3:38 PM
Contrasting Spring Bank Pharmaceuticals (SBPH) & Rhythm Pharmaceuticals (RYTM)Contrasting Spring Bank Pharmaceuticals (SBPH) & Rhythm Pharmaceuticals (RYTM)
www.americanbankingnews.com - April 13 at 3:15 AM
Spring Bank Pharmaceuticals (SBPH) Downgraded by ValuEngineSpring Bank Pharmaceuticals (SBPH) Downgraded by ValuEngine
www.americanbankingnews.com - April 10 at 7:17 PM
Spring Bank Pharmaceuticals (SBPH) Upgraded by ValuEngine to "Hold"Spring Bank Pharmaceuticals (SBPH) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 5 at 10:26 AM
Spring Bank Pharmaceuticals Inc (SBPH) Given Average Recommendation of "Buy" by BrokeragesSpring Bank Pharmaceuticals Inc (SBPH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 10:15 AM
 Analysts Anticipate Spring Bank Pharmaceuticals Inc (SBPH) to Post -$0.52 EPS Analysts Anticipate Spring Bank Pharmaceuticals Inc (SBPH) to Post -$0.52 EPS
www.americanbankingnews.com - April 3 at 3:10 PM
Spring Bank Pharmaceuticals (SBPH) Now Covered by B. RileySpring Bank Pharmaceuticals (SBPH) Now Covered by B. Riley
www.americanbankingnews.com - April 1 at 8:42 PM
Spring Bank Pharmaceuticals (SBPH) Buy Rating Reaffirmed at Chardan CapitalSpring Bank Pharmaceuticals' (SBPH) Buy Rating Reaffirmed at Chardan Capital
www.americanbankingnews.com - April 1 at 7:35 PM
Edited Transcript of SBPH earnings conference call or presentation 21-Feb-18 1:30pm GMTEdited Transcript of SBPH earnings conference call or presentation 21-Feb-18 1:30pm GMT
finance.yahoo.com - April 1 at 9:51 AM
Zacks: Analysts Anticipate Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.52 Per ShareZacks: Analysts Anticipate Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - March 17 at 1:30 PM
Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative PatientsSpring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
finance.yahoo.com - March 14 at 12:39 PM
Spring Bank Pharmaceuticals Inc (SBPH) Given Average Rating of "Buy" by AnalystsSpring Bank Pharmaceuticals Inc (SBPH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 11 at 10:10 AM
Head-To-Head Comparison: Auspex Pharmaceuticals (ASPX) & Spring Bank Pharmaceuticals (SBPH)Head-To-Head Comparison: Auspex Pharmaceuticals (ASPX) & Spring Bank Pharmaceuticals (SBPH)
www.americanbankingnews.com - March 10 at 9:22 PM
Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of DirectorsSpring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors
finance.yahoo.com - March 5 at 4:24 PM
Spring Bank Pharmaceuticals Inc (SBPH) Insider Martin J. Driscoll Acquires 1,000 SharesSpring Bank Pharmaceuticals Inc (SBPH) Insider Martin J. Driscoll Acquires 1,000 Shares
www.americanbankingnews.com - March 1 at 10:44 PM
Zacks: Brokerages Anticipate Spring Bank Pharmaceuticals Inc (SBPH) to Post -$0.52 Earnings Per ShareZacks: Brokerages Anticipate Spring Bank Pharmaceuticals Inc (SBPH) to Post -$0.52 Earnings Per Share
www.americanbankingnews.com - February 28 at 1:40 PM
William Blair Brokers Boost Earnings Estimates for Spring Bank Pharmaceuticals Inc (SBPH)William Blair Brokers Boost Earnings Estimates for Spring Bank Pharmaceuticals Inc (SBPH)
www.americanbankingnews.com - February 26 at 1:48 AM
Spring Bank Pharmaceuticals Inc (SBPH) to Post FY2018 Earnings of ($2.31) Per Share, B. Riley ForecastsSpring Bank Pharmaceuticals Inc (SBPH) to Post FY2018 Earnings of ($2.31) Per Share, B. Riley Forecasts
www.americanbankingnews.com - February 23 at 12:28 PM
Spring Bank Pharmaceuticals Inc Forecasted to Post FY2022 Earnings of $0.55 Per Share (SBPH)Spring Bank Pharmaceuticals Inc Forecasted to Post FY2022 Earnings of $0.55 Per Share (SBPH)
www.americanbankingnews.com - February 22 at 4:34 PM
Spring Bank Pharmaceuticals (SBPH) Price Target Increased to $32.00 by Analysts at Cantor FitzgeraldSpring Bank Pharmaceuticals (SBPH) Price Target Increased to $32.00 by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - February 21 at 2:44 PM
Spring Bank Pharmaceuticals, Inc. to Host Earnings CallSpring Bank Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - February 21 at 10:34 AM
Spring Bank Pharmaceuticals Inc (SBPH) Given Consensus Rating of "Buy" by BrokeragesSpring Bank Pharmaceuticals Inc (SBPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 14 at 11:00 AM
Spring Bank Pharmaceuticals Inc (SBPH) Receives Average Recommendation of "Buy" from AnalystsSpring Bank Pharmaceuticals Inc (SBPH) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 20 at 8:08 AM
Spring Bank Strengthens Management Team to Enhance OperationsSpring Bank Strengthens Management Team to Enhance Operations
finance.yahoo.com - January 9 at 10:41 AM
Spring Bank Pharmaceuticals Inc (SBPH) Expected to Announce Earnings of -$0.55 Per ShareSpring Bank Pharmaceuticals Inc (SBPH) Expected to Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - January 8 at 5:04 PM
 Brokerages Anticipate Spring Bank Pharmaceuticals Inc (SBPH) Will Announce Earnings of -$0.55 Per Share Brokerages Anticipate Spring Bank Pharmaceuticals Inc (SBPH) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - December 23 at 9:18 AM
 Brokerages Expect Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.53 Per Share Brokerages Expect Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.53 Per Share
www.americanbankingnews.com - December 5 at 3:30 PM
Spring Bank Pharmaceuticals (SBPH) Rating Lowered to Sell at ValuEngineSpring Bank Pharmaceuticals (SBPH) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 2 at 6:16 PM
Spring Bank Pharmaceuticals, Inc. (SBPH) Given Average Recommendation of "Buy" by BrokeragesSpring Bank Pharmaceuticals, Inc. (SBPH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 1 at 4:30 PM
Spring Bank Pharmaceuticals (SBPH) and PTC Therapeutics (PTCT) Critical ContrastSpring Bank Pharmaceuticals (SBPH) and PTC Therapeutics (PTCT) Critical Contrast
www.americanbankingnews.com - November 30 at 1:28 AM
Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE TrialSpring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
finance.yahoo.com - November 18 at 11:38 AM
Zacks: Brokerages Anticipate Spring Bank Pharmaceuticals, Inc. (SBPH) to Post -$0.53 Earnings Per ShareZacks: Brokerages Anticipate Spring Bank Pharmaceuticals, Inc. (SBPH) to Post -$0.53 Earnings Per Share
www.americanbankingnews.com - November 17 at 9:30 PM
Spring Bank Pharmaceuticals, Inc. (SBPH) Given a $29.00 Price Target by Cantor Fitzgerald AnalystsSpring Bank Pharmaceuticals, Inc. (SBPH) Given a $29.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - November 16 at 10:38 AM
Analysts Set Expectations for Spring Bank Pharmaceuticals, Inc.s FY2017 Earnings (SBPH)Analysts Set Expectations for Spring Bank Pharmaceuticals, Inc.'s FY2017 Earnings (SBPH)
www.americanbankingnews.com - November 8 at 11:04 AM
Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare ConferenceSpring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference
finance.yahoo.com - November 7 at 9:58 AM
Spring Bank Pharmaceuticals, Inc. (SBPH) Receives Consensus Recommendation of "Buy" from AnalystsSpring Bank Pharmaceuticals, Inc. (SBPH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 6 at 10:46 AM
William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.s FY2017 Earnings (SBPH)William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.'s FY2017 Earnings (SBPH)
www.americanbankingnews.com - November 6 at 2:54 AM
Head to Head Review: Spring Bank Pharmaceuticals (SBPH) versus Its PeersHead to Head Review: Spring Bank Pharmaceuticals (SBPH) versus Its Peers
www.americanbankingnews.com - November 3 at 9:14 PM
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational ResultsSpring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results
finance.yahoo.com - October 31 at 9:08 AM
Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD ConferenceSpring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
finance.yahoo.com - October 20 at 4:57 PM
Critical Comparison: Summit Therapeutics PLC (SMMT) & Spring Bank Pharmaceuticals (SBPH)Critical Comparison: Summit Therapeutics PLC (SMMT) & Spring Bank Pharmaceuticals (SBPH)
www.americanbankingnews.com - October 15 at 10:26 PM
Financial Analysis: Spring Bank Pharmaceuticals (SBPH) & Its CompetitorsFinancial Analysis: Spring Bank Pharmaceuticals (SBPH) & Its Competitors
www.americanbankingnews.com - October 14 at 6:08 AM
Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and ImmunotherapySpring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy
finance.yahoo.com - October 6 at 8:51 AM
Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.
finance.yahoo.com - October 6 at 8:51 AM
ROTY Volume 1 Edition 33: New Leadership In The Model Account, Changes To Format And TradesROTY Volume 1 Edition 33: New Leadership In The Model Account, Changes To Format And Trades
seekingalpha.com - September 29 at 11:15 AM
William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.s Q1 2018 Earnings (SBPH)William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.'s Q1 2018 Earnings (SBPH)
www.americanbankingnews.com - September 29 at 8:48 AM
Financial Survey: Spring Bank Pharmaceuticals (SBPH) versus AveXis (AVXS)Financial Survey: Spring Bank Pharmaceuticals (SBPH) versus AveXis (AVXS)
www.americanbankingnews.com - September 29 at 6:42 AM
Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MASpring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA
finance.yahoo.com - September 20 at 8:44 AM
Chardan Capital Reaffirms Buy Rating for Spring Bank Pharmaceuticals, Inc. (SBPH)Chardan Capital Reaffirms Buy Rating for Spring Bank Pharmaceuticals, Inc. (SBPH)
www.americanbankingnews.com - September 20 at 6:26 AM

SEC Filings

Spring Bank Pharmaceuticals (NASDAQ:SBPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Spring Bank Pharmaceuticals (NASDAQ SBPH) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.